Operating Expenses

R&D

Fair Isaac R&D increased by 8.0% to $53.92M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $45.04M to $53.92M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 2.4% CAGR.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026

How to read this metric

Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.

Detailed definition

Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...

Peer comparison

Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.

Metric ID: research_and_development

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$45.83M$41.14M$38.98M$36.39M$35.88M$35.51M$36.63M$40.27M$41.46M$41.60M$42.64M$40.88M$44.22M$44.21M$45.15M$45.04M$47.21M$50.95M$49.91M$53.92M
QoQ Change-10.2%-5.3%-6.7%-1.4%-1.0%+3.2%+9.9%+3.0%+0.3%+2.5%-4.1%+8.2%-0.0%+2.1%-0.2%+4.8%+7.9%-2.0%+8.0%
YoY Change-21.7%-13.7%-6.0%+10.7%+15.5%+17.1%+16.4%+1.5%+6.7%+6.3%+5.9%+10.2%+6.8%+15.3%+10.6%+19.7%
Range$35.51M$53.92M
CAGR+3.5%
Avg YoY Growth+6.3%
Median YoY Growth+8.5%

Frequently Asked Questions

What is Fair Isaac's r&d?
Fair Isaac (FICO) reported r&d of $53.92M in Q1 2026.
How has Fair Isaac's r&d changed year-over-year?
Fair Isaac's r&d increased by 19.7% year-over-year, from $45.04M to $53.92M.
What is the long-term trend for Fair Isaac's r&d?
Over 4 years (2021 to 2025), Fair Isaac's r&d has grown at a 2.4% compound annual growth rate (CAGR), from $171.23M to $188.35M.
What does r&d mean?
The money spent on creating new products or improving existing ones to drive future growth.